Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18354908 | 0.95 | HCAR2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL18352684 | 0.83 | SMN1; SMN2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL18353038 | 0.83 | CHRNB2 (0.38) | CHRNB2CHRNA4SMN1; SMN2HCAR2ATM | |
| SCHEMBL18353215 | 0.82 | TSHR (0.34) | HCAR2ATMTSHRALDH1A1MAPT | |
| SCHEMBL18352689 | 0.79 | TSHR (0.34) | HCAR2ATMTSHR | |
| SCHEMBL18355269 | 0.79 | SMN1; SMN2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL18355352 | 0.79 | HCAR2 (0.41) | CHRNB2CHRNA4SMN1; SMN2HCAR2ATM | |
| SCHEMBL18354906 | 0.78 | HCAR2 (0.39) | SMN1; SMN2HCAR2TSHRALDH1A1MAPT | |
| SCHEMBL18094742 | 0.78 | TSHR (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4SMN1; SMN2 | |
| SCHEMBL18352526 | 0.78 | MAPT (0.51) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001952-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | CHRNB2 2170/4885CHRNB4 2401/4885CHRNA3 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.